Back to top

Merck & Co. (MRK)

(Delayed Data from NYSE)

$103.46 USD


+0.98 (0.96%)

Updated Dec 1, 2023 04:00 PM ET

After-Market: $103.45 -0.01 (-0.01%) 5:28 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.96%
5Strong Sell2.32%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value A Growth B Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 29% (72 out of 251)

Industry: Large Cap Pharmaceuticals

Better trading starts here.

Zacks News

Kinjel Shah headshot

Pharma Stock Roundup: ABBV to Buy Immunogen, NVS Ups Mid-Term Sales View & More

AbbVie (ABBV) offers to acquire cancer biotech Immunogen for $10.1 billion. Novartis (NVS) raises its mid-term sales growth outlook by 1%.

Seagen's (SGEN) Combo Drug Expanded-Use sBLA Gets Priority Tag

Seagen (SGEN) and Astellas Pharma announce that the FDA has accepted the label expansion-seeking application for the Padcev/Keytruda combo under priority review to treat first-line bladder cancer.

Merck's (MRK) Pneumococcal Jab Shows Upbeat Responses in Study

Positive data from Merck's (MRK) phase III study on V116, an investigational, 21-valent pneumococcal conjugate vaccine, supports the immunogenicity of V116 compared to standard of care.

Kinjel Shah headshot

Pharma Stock Roundup: NVO & LLY to Expand Manufacturing Capacity in Europe, & More

Eli Lilly (LLY) plans to build a $2.5 billion manufacturing plant in Germany. Novo Nordisk (NVO) plans to invest $2.3 billion to expand an existing production site in France.

Merck (MRK) to Acquire Private Neuroscience Company for $610M

Merck (MRK) has been a shareholder in Caraway Therapeutics since 2018 through its MRL Ventures Fund.

Merck (MRK) Gets FDA Nod for Keytruda Expansion in Gastric Cancer

Following this approval, Merck's (MRK) Keytruda is approved for seven gastrointestinal cancers. Overall, the drug is approved for 38 indications in the country.

Kinjel Shah headshot

Pharma Stock Roundup: FDA Okays AZN's Capivasertib & MRK's Keytruda Expanded Use

FDA approves AstraZeneca's (AZN) new breast cancer drug, Truqap, and the expanded use of Merck's (MRK) Keytruda in a gastric cancer indication

Is Nuveen ESG Large-Cap Value ETF (NULV) a Strong ETF Right Now?

Smart Beta ETF report for NULV

Bristol Myers (BMY) Receives FDA Approval for NSCLC Drug

Bristol Myers' (BMY) repotrectinib, a tyrosine kinase inhibitor (???TKI???) targeting ROS1 oncogenic fusions, gets FDA???s approval for NSCLC.

AstraZeneca (AZN) Beats on Q3 Earnings & Sales, Ups 2023 View

AstraZeneca (AZN) beats third-quarter estimates for earnings and sales. The company raises its sales and EPS guidance for 2023.

Is Vident U.S. Equity Strategy ETF (VUSE) a Strong ETF Right Now?

Smart Beta ETF report for VUSE

The Zacks Analyst Blog Highlights McDonald's, ConocoPhillips, RTX, Merck and Emerson Electric

McDonald's, ConocoPhillips, RTX, Merck and Emerson Electric are included in this Analyst Blog.

Ligand (LGND) Beats on Q3 Earnings & Sales, Raises '23 View

Ligand Pharmaceuticals (LGND) reports encouraging third-quarter results as earnings and sales beat estimates. Management raises the 2023 financial outlook.

Sheraz Mian headshot

Top Analyst Reports for McDonald's, ConocoPhillips & RTX

Today's Research Daily features new research reports on 16 major stocks, including McDonald's Corporation (MCD), ConocoPhillips (COP) and RTX Corporation (RTX).

Mirati's (MRTX) Q3 Loss Narrows, Sales Miss Expectations

Mirati (MRTX) posts mixed third-quarter results as the bottom line exceeds estimates while the top line misses.

AstraZeneca (AZN) to Report Q3 Earnings: What's in the Cards?

Higher sales of AstraZeneca's (AZN) key medicines, Lynparza, Tagrisso, Imfinzi and Farxiga, are likely to have driven sales in the third quarter, partially offset by lower sales of legacy drugs.

The Zacks Analyst Blog Highlights Merck, Bank of America, AMD, Netflix and Union Pacific

Merck, Bank of America, AMD, Netflix and Union Pacific are part of the Zacks top Analyst Blog.

Sheraz Mian headshot

Q3 Earnings Season Scorecard and Analyst Reports for Merck, Bank of America & AMD

Today's Research Daily features the Q3 earnings season scorecard and new research reports on Merck (MRK), Bank of America (BAC), AMD (AMD) and others.

Moderna (MRNA) Beats on Q3 Earnings & Sales, Expects Lower COVID Demand

Moderna (MRNA) beats expectations for earnings and sales. However, the company projects lower-than-expected 2024 guidance, which likely led to a decline in share price after the earnings announcement.

Corcept (CORT) Beats on Q3 Earnings, Raises '23 Sales View

Corcept's (CORT) third-quarter 2023 earnings and revenues surpass estimates. The company raises the full-year revenue guidance for 2023.

Kinjel Shah headshot

Pharma Stock Roundup: SNY, MRK, NVS Report Q3 Earnings, FDA Okays PFE, LLY Products

Merck (MRK), Sanofi (SNY) and Novartis (NVS) report third-quarter results. FDA approves Pfizer's (PFE) Penbraya and Eli Lilly's (LLY) Omvoh

Company News for Oct 27, 2023

Companies in The News Are: MRK, UPS, IBM, CBRE

Merck (MRK) Q3 Earnings Top Estimates, COVID Drug Boosts Sales

Merck (MRK) beats Q3 estimates for earnings and sales. It raises its 2023 guidance. Stock rises in pre-market.

Merck (MRK) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates

Although the revenue and EPS for Merck (MRK) give a sense of how its business performed in the quarter ended September 2023, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Merck (MRK) Q3 Earnings and Revenues Beat Estimates

Merck (MRK) delivered earnings and revenue surprises of 9.79% and 3.80%, respectively, for the quarter ended September 2023. Do the numbers hold clues to what lies ahead for the stock?